Key result
Coating commercial polymers with antiplatelet drugs and apyrase yields nonthrombogenic surfaces in preclinical testing.
Why the study?
Platelet adhesion and aggregation on polymer surfaces lead to thrombosis, necessitating development of nonthrombogenic polymer modifications.
Answers are grounded in this paper and cite their sources.
Modification of polymer surfaces with antiaggregating agents and apyrase may provide a method for creating nonthrombogenic materials for blood-contacting devices.
Platelet adhesion and aggregation are very important steps of thrombosis. Platelet adhesion onto foreign surfaces takes place as soon as these latter are in contact with blood. As a result of this interaction, the platelets release ADP and serotonin, which apparently cause subsequent platelet aggregation. For polymer surface modifications we have experienced ditazole and dipyridamole which are effective platelet aggregating agents. Apyrase which catalyzes the transformation of ADP into AMP and then to adenosine was also experienced. The preparation of nonthrombogenic surfaces starting from commercially available polymers such as cellulose, cellulose triacetate, nylon and polyethyleneterephtalate by addition of platelet antiaggregating drugs and apyrase is described together with their in vitro and in vivo characterization.
No takes yet. Share an insight, caveat, or question.
W. Marconi (1981) studied Thrombosis. Nonthrombogenic polymer compositions (polymers with ditazole, dipyridamole, and apyrase) was evaluated on In vitro and in vivo characterization of nonthrombogenic surfaces. Nonthrombogenic surfaces were successfully prepared from commercially available polymers by adding platelet antiaggregating drugs and apyrase, and characterized in vitro and in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: